Latin America Biochips Market (2025-2030)
The Latin America Biochips Market was valued at $540.4 Million in 2025 and projected to reach to $795.5 Million by 2030, representing a compound annual growth rate of 8.0%. Latin America's biochips market is positioned for sustained growth driven by expanding healthcare infrastructure investments and increasing prevalence of chronic diseases requiring advanced diagnostic capabilities.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Latin America Biochips Market Trends and Insights
- Latin America's biochips sector is driven by increasing healthcare investments, rising prevalence of chronic diseases, and growing adoption of point-of-care diagnostic technologies across the region.
- In 2025, Latin America accounts for a meaningful share of emerging market biochips demand, with diagnostic and therapeutic applications gaining traction among healthcare providers seeking cost-effective solutions. By 2030, Latin America is expected to solidify its position as a key growth market within the global biochips landscape.
- Latin America's market expansion is supported by improving healthcare infrastructure, regulatory framework development, and partnerships between local healthcare systems and international biochip manufacturers.
- The region's growing middle class and increased healthcare spending are creating favorable conditions for biochip adoption in clinical diagnostics, personalized medicine, and drug discovery applications throughout Latin America..
Key Market Statistics
- CAGR (2025-2030) 8.0% CAGR
- Market Size, 2025 ~USD 540.4 Million
- Forecast, 2030 ~USD 795.5 Million
- Geography Latin America
Latin America Biochips Market Overview
Market Valuation & Growth :
Latin America's biochips market is valued at $540.4 million in 2025 and is projected to reach $795.5 million by 2030, growing at a steady 8.0% CAGR, slightly below the global average of 8.8%.
Healthcare Investment Surge :
Increasing government and private healthcare investments across Latin America are driving adoption of advanced diagnostic technologies, particularly in emerging economies seeking to modernize their healthcare infrastructure.
Chronic Disease Prevalence :
Rising incidence of diabetes, cardiovascular diseases, and cancer across Latin America is accelerating demand for rapid, accurate diagnostic solutions that biochips technology provides.
Point-of-Care Diagnostics Expansion :
Growing adoption of point-of-care testing technologies in Latin America is enabling decentralized healthcare delivery, improving accessibility in remote and underserved regions across the continent.
Latin America Biochips Market Dynamics
- The region's adoption of point-of-care diagnostic technologies is accelerating, particularly in Brazil and Mexico, where healthcare modernization initiatives are creating significant opportunities for biochip manufacturers and distributors. Over the forecast period through 2030, Latin America is expected to benefit from rising healthcare expenditures, improved regulatory frameworks, and growing awareness of precision medicine.
- Strategic partnerships between regional healthcare providers and international biochip companies will further strengthen market penetration, while local manufacturing initiatives may emerge to reduce costs and improve accessibility across the region..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- Latin America's biochips market is valued at $540.4 million in 2025 and will grow to $795.5 million by 2030 at an 8.0% CAGR.
- Latin America is experiencing increased adoption of point-of-care diagnostic biochips driven by healthcare infrastructure improvements and chronic disease prevalence.
- Latin America's market growth is supported by regulatory development, international partnerships, and rising healthcare expenditure across the region.
- Latin America represents a strategic emerging market opportunity for biochip manufacturers targeting diagnostic, therapeutic, and personalized medicine applications.
Biochips Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | MICROFLUIDICS (Fabrication Technology) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 8.8% from 2025 to 2030 |
| Largest Segment | MICROARRAYS (Fabrication Technology) |
| Market Size Base Year (Billions) | ~USD 14.01 (2025) |
| Revenue Forecast (Billions) | ~USD 21.36 (2030) |
| Segments Covered | Products & Services, Type, Application, Fabrication Technology, End User, Product & Service |
Latin America Biochips Market Report Segmentation
6 segment dimensions are covered across the global market.
By Products & Services
- Consumables
- Instruments
- Software & Services
By Type
- Cell Arrays
- Dna Chips
- Lab-On-A-Chip
- Protein Chips
- Tissue Arrays
By Application
- Agricultural Biotechnology
- Cancer Diagnosis & Treatment
- Clinical Diagnostic
- Diagnostics
- Drug Discovery
- Expression Profiling
- Gene Expression
- Genomics
- High-Throughput Screening
- Ivd & Poc
- Other Dna Chip Applications
- Other Loac Applications
- Other Protein Chip Applications
- Proteomics
- Snp Genotyping
By Fabrication Technology
- Microarrays
- Microfluidics
By End User
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
- Contract Research Organizations
- Hospitals & Diagnostic Centers
- Other End Users
By Product & Service
- Consumables
- Instruments
- Software & Services
Target Audience
- Biochip Manufacturers & Suppliers : Manufacturers need Latin America-specific market data to identify expansion opportunities, assess competitive positioning, and develop localized product strategies for the region's growing healthcare sector.
- Healthcare Providers & Hospital Networks : Hospital systems and diagnostic centers require market insights to evaluate biochip technology adoption, benchmark against regional peers, and plan diagnostic infrastructure investments.
- Medical Device Distributors : Regional and national distributors need country-level market sizing and growth forecasts to optimize inventory, negotiate supplier agreements, and identify high-potential market segments.
- Healthcare Investment & Private Equity Firms : Investors evaluating Latin American healthcare opportunities require detailed market analysis, growth projections, and competitive intelligence to assess investment returns and portfolio positioning.
- Government & Healthcare Policy Makers : Regional health authorities and policy makers need market data to inform healthcare modernization initiatives, regulatory frameworks, and technology adoption strategies across Latin America.
Key Companies in the Latin America Biochips Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ATS AUTOMATION TOOLING SYSTEMS INC | Canada | Public Company | Custom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions, |
| DECODE GENETICS | Iceland | Private Company | Internal discovery and target validation for Amgen,External research collaborations and licensing,Population genomics and healthcare-linked projects, |
| JABIL | United States | Public Company | Regulated Industries (Healthcare, Automotive, Industrial, Packaging),Intelligent Infrastructure (5G, Cloud, Networking, Storage, Digital Building),Connected Living and Digital Commerce (Mobility, Connected Devices, Retail, Digital Commerce Ecosystem), |
| AT&S | Canada | Public Company | Turnkey automation systems (design, build, commissioning),Lifecycle services (pre- and post-automation, maintenance, retrofits),Contract manufacturing and integration, |
| X-FAB | Belgium | Public Company | Automotive analog & mixed-signal (incl. high-voltage, BCD, safety ICs),Power semiconductors (SiC, GaN, high-voltage discretes),MEMS & sensor platforms (pressure, inertial, image, gas/flow, photodiodes), |
| GE HEALTHCARE | United States | Public Company | Imaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response (TB and transplant) assays,Oncology, sexual and reproductive health assays, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics systems, reagents, and quality controls,Life Science instruments and consumables for research and biopharma,Informatics and software solutions, |
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| STANDARD BIOTOOLS | United States | Public Company | Proteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and qPCR systems),Services, software, and other, |
| 10X GENOMICS | United States | Public Company | Chromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, reagents), |
| CEPHEID | United States | Private Company | GeneXpert instruments,Xpert test cartridges (infectious disease & HAIs),Xpert test cartridges (virology, oncology, genetics), |
| BIOMéRIEUX | France | Public Company | Clinical microbiology (VITEK, BACT/ALERT, CHROMID, culture media, ETEST, API),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, EPISEQ),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA), |
| REVVITY | United States | Public Company | Diagnostics & Immunodiagnostics (prenatal, newborn, infectious, autoimmune, specialty),Life Science Reagents & Assay Platforms,Genomic & NGS Workflow Solutions, |
| DIASORIN S.P.A. | Italy | Public Company | Immunodiagnostics (LIAISON XL / XS reagents and systems),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other specialty IVD solutions, |
ATS AUTOMATION TOOLING SYSTEMS INC
ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.
DECODE GENETICS
Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company focuses on genetic research and analysis.
JABIL
Jabil is a large American public company founded in 1966 with 135,000 employees. The company provides electronics manufacturing services and solutions.
AT&S
AT&S is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.
X-FAB
X-FAB is a Belgian public semiconductor company founded in 1992 with 4,300 employees. The company manufactures specialty semiconductor products.
GE HEALTHCARE
GE Healthcare is an American public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.
ILLUMINA, INC.
Illumina, Inc. is an American public company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is an American public company founded in 1999 with 18,000 employees. The company provides analytical instruments and software for life sciences and diagnostics.
QIAGEN
Qiagen is a Dutch public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation products.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is an American public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.
ABBOTT
Abbott is a large American public company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, and medical devices.
STANDARD BIOTOOLS
Standard Biotools is an American public company founded in 1999 with 387 employees. The company develops microfluidic and single-cell analysis solutions.
10X GENOMICS
10X Genomics is an American public company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions.
CEPHEID
Cepheid is an American private company founded in 1996 with 1,700 employees. The company manufactures molecular diagnostics and point-of-care testing systems.
BIOMéRIEUX
bioMérieux is a French public company founded in 1963 with 14,894 employees. The company develops and manufactures in vitro diagnostics and microbiology testing systems.
REVVITY
Revvity is an American public company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.
DIASORIN S.P.A.
DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company develops and manufactures in vitro diagnostic products.
Countries within Latin America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Brazil | USD 501.6 Million |
| Mexico | USD 120.5 Million |
| Rest Of Latin America | USD 173.5 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Sizing & Forecasts : Obtain precise market valuations for Latin America ($540.4M in 2025) with country-level breakdowns for Brazil, Mexico, and Rest of Latin America, enabling targeted investment and expansion strategies.
- Growth Opportunity Identification : Identify high-growth segments within Latin America's 8% CAGR market, including point-of-care diagnostics and chronic disease management applications driving regional demand.
- Competitive Landscape Analysis : Understand market dynamics specific to Latin America, including key players, market consolidation trends, and competitive positioning to inform go-to-market strategies.
- Healthcare Investment Trends : Access insights on Latin American government healthcare spending, regulatory developments, and infrastructure modernization initiatives shaping biochips adoption across the region.
- Country-Level Market Intelligence : Leverage detailed market data for Brazil ($501.6M), Mexico ($120.5M), and other Latin American countries to prioritize market entry and resource allocation decisions.
Frequently asked questions
What is the current size of the biochips market in Latin America?
The Latin America biochips market is valued at $540.4 million in 2025, with strong growth projected through 2030.
What is the expected growth rate for biochips in Latin America?
Latin America's biochips market is expected to grow at an 8.0% CAGR from 2025 to 2030, reaching $795.5 million by forecast year end.
What are the primary drivers of biochips market growth in Latin America?
Latin America's biochips growth is driven by increasing healthcare investments, rising chronic disease prevalence, improving infrastructure, regulatory development, and growing adoption of point-of-care diagnostics.
Which biochip applications are most prevalent in Latin America?
Latin America is seeing strong adoption of diagnostic biochips for point-of-care testing, alongside emerging applications in personalized medicine and drug discovery.
How does Latin America's biochips market compare to global growth?
Latin America's 8.0% CAGR is slightly below the global 8.8% CAGR, reflecting the region's emerging market status and developing healthcare infrastructure relative to mature markets.
RESEARCH METHODOLOGY
This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.
Secondary Research
This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the biochips market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.
Primary Research
In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the biochips market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes and contract research organizations.
A breakdown of the primary respondents is provided below:
Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biochips market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
The biochips market refers to miniaturized analytical platforms integrating biological probes or microfluidic components that allow simultaneous or rapid analysis of DNA, RNA, proteins, metabolites, or tissues. They are fabricated as microarrays, microfluidic cartridges, or tissue arrays and used in diagnostics, genomics, proteomics, drug discovery, and pathology research. These biochips enable high-throughput screening, providing faster, more efficient testing methods, and are critical in applications such as personalized medicine, disease detection, and environmental monitoring. With advances in technology, biochips are becoming increasingly versatile, supporting the development of novel diagnostics and therapeutic solutions across multiple sectors.
Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutes
- Academic Institutes
- Contract Research Organizations
- Research and Consulting Companies
- Biochip Manufacturers and Distributors
- DNA & Gene Chip Manufacturers and Distributors
- Protein Microarray Manufacturers and Distributors
- Lab-on-a-Chip Manufacturers and Distributors
- Cell & Tissue Array Manufacturers and Distributors
Report Objectives
- To define, describe, segment, and forecast the biochips market by products & services, type, fabrication technology, end user, and region
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biochips market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the biochips market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the biochips market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships
Get the Full Biochips Market Report
Full forecast, segment splits, and company analysis for all Biochips Market.
- Canada Biochips Market
- US Biochips Market
- Germany Biochips Market
- UK Biochips Market
- France Biochips Market
- Italy Biochips Market
- Spain Biochips Market
- Netherlands Biochips Market
- China Biochips Market
- Japan Biochips Market
- India Biochips Market
- Australia Biochips Market
- South Korea Biochips Market
- Thailand Biochips Market
- New Zealand Biochips Market
- Brazil Biochips Market
- Mexico Biochips Market
- Rest Of Europe Biochips Market
- Rest Of Asia Pacific Biochips Market
- Rest Of Latin America Biochips Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
